Sökning: onr:"swepub:oai:DiVA.org:umu-168136" >
Mid-regional proatr...
Mid-regional proatrial natriuretic peptide for predicting prognosis in hypertrophic cardiomyopathy
-
Begue, Celine (författare)
-
- Mörner, Stellan (författare)
- Umeå universitet,Kardiologi
-
Brito, Dulce (författare)
-
visa fler...
-
Hengstenberg, Christian (författare)
-
Cleland, John G. F. (författare)
-
Arbustini, Eloisa (författare)
-
Galve, Enrique (författare)
-
Wichter, Thomas (författare)
-
Richter, Anette (författare)
-
Golmard, Jean-Louis (författare)
-
Bernard, Maguy (författare)
-
Dubourg, Olivier (författare)
-
Komajda, Michel (författare)
-
Charron, Philippe (författare)
-
Isnard, Richard (författare)
-
visa färre...
-
(creator_code:org_t)
- 2019-07-26
- 2020
- Engelska.
-
Ingår i: Heart. - : BMJ PUBLISHING GROUP. - 1355-6037 .- 1468-201X. ; 106:3, s. 196-202
- Relaterad länk:
-
http://eprints.gla.a...
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Objectives N-terminal probrain natriuretic peptide (NT-proBNP) predicts mortality and the development of heart failure in hypertrophic cardiomyopathy (HCM). Mid-regional proatrial natriuretic peptide (MR-proANP) is a stable by-product of production of atrial natriuretic peptide. We sought to compare the prognostic value of MR-proANP and NT-proBNP in HCM. Methods We prospectively enrolled a cohort of patients with HCM from different European centres and followed them. All patients had clinical, ECG and echocardiographic evaluation and measurement of MR-proANP and NT-proBNP at inclusion. Results Of 357 patients enrolled, the median age was 52 (IQR: 36-65) years. MR-proANP and NT-proBNP were both independently associated with age, weight, New York Heart Association (NYHA) class, left ventricular ejection fraction (LVEF), wall thickness and left atrial dimension. During a median follow-up of 23 months, 32 patients had a primary end point defined as death (n=6), heart transplantation (n=8), left ventricular assist device implantation (n=1) or heart failure hospitalisation (n=17). Both NT-proBNP and MR-proANP (p<10(-4)) were strongly associated with the primary endpoint, and the areas under the receiver operating characteristic (ROC) curves for both peptides were not significantly different. However, in a multiple stepwise regression analysis, the best model for predicting outcome was NYHA 1-2 vs 3-4 (HR=0.35, 95% CI 0.16 to 0.77, p<0.01), LVEF (HR=0.96, 95% CI 0.94 to 0.98, p=0.0005) and MR-proANP (HR=3.77, 95% CI 2.01 to 7.08, p<0.0001). Conclusions MR-proANP emerges as a valuable biomarker for the prediction of death and heart failure related events in patients with HCM.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kardiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)
Nyckelord
- natriuretic peptide
- MR-proANP
- NT-proBNP
- hypertrophic cardiomyopathy
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
-
Heart
(Sök värdpublikationen i LIBRIS)
Till lärosätets databas
- Av författaren/redakt...
-
Begue, Celine
-
Mörner, Stellan
-
Brito, Dulce
-
Hengstenberg, Ch ...
-
Cleland, John G. ...
-
Arbustini, Elois ...
-
visa fler...
-
Galve, Enrique
-
Wichter, Thomas
-
Richter, Anette
-
Golmard, Jean-Lo ...
-
Bernard, Maguy
-
Dubourg, Olivier
-
Komajda, Michel
-
Charron, Philipp ...
-
Isnard, Richard
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Kardiologi
- Artiklar i publikationen
-
Heart
- Av lärosätet
-
Umeå universitet